Asthma Screening Study
Future Participant Registry

IRB No. HUM00211543

Investigator Initiated | Lugogo

Proactively evaluate potential subjects with asthma who have expressed interest in participating in clinical asthma research trials at Michigan Medicine.

Studies Currently Enrolling
Therapeutic Trials

AJAX

IRB No. HUM00244175

AstraZeneca | D8210C00003 | Lugogo

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

ATLAS

IRB No. HUM00206820

Sanofi | LPS16676 | Lugogo

Study assessing the long-term effect of Dupilumab (Dupixent) on prevention of lung function decline in patients with uncontrolled moderate to severe asthma.

ATLAS

CHINOOK

IRB No. HUM00196809

AstraZeneca | D3250C00059 | Lugogo

Study designed to evaluate the effect of Benralizumab (Fasenra) on patients with uncontrolled severe, eosinophilic asthma despite a high dose ICS-based treatment regimen with an eosinophilic phenotype.

CHINOOK

NEW Study Now Enrolling!

ANCHOR

IRB No. HUM00262890

AstraZeneca | D6930L00001 | Lugogo

Primary Objective: Describe and compare asthma exacerbation rates in the 12 months pre-period to the 12 months post-period among participants switching from SABA only rescue inhaler albuterol or levalbuterol to AIRSUPRA.

The patient will receive an Rx Study card that allows them to fill their AIRSUPRA at no cost during the 12 month participation period. The ANCHOR Study team will reach out to the patient every 3 months to gather study-related information.

ANCHOR